You are now leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?

search-icon
search-icon
hemgenix-logo-bg mobile-menu-bg HEMGENIX® (etranacogene dezaparvovec-drlb)

HEMGENIX CAN ELIMINATE THE NEED FOR PROPHYLAXIS IN YOUR LIFE BY ALLOWING YOU TO MAKE YOUR OWN FACTOR IX

HEMGENIX DNA Spiral with People holding hands
David
Consistent
factor IX level of
37% for years
Patient portrayal;
HEMGENIX not
intended for women
Icon of video player

Meet people who have redefined how they live with hemophilia B thanks to HEMGENIX

Watch their stories
Icon of a bar chart

See how a one-time infusion can provide greater bleed protection and can also eliminate prophylaxis from your life.*

Long-term results
$0 out-of-pocket cost

Eligible patients pay $0 out of pocket for HEMGENIX. Most patients with commercial insurance can enjoy this benefit.†

Enroll in support

* In the clinical trial, 54 adult males with moderately severe to severe hemophilia B received a single dose of HEMGENIX. Annualized bleed rate (ABR) for all bleeds decreased from an average of 4.1 for patients on prophylaxis during the lead-in period to 1.9 (54% reduction) in months 7–18 after treatment.

† $0 out-of-pocket cost for most commercially insured people. Subject to terms and conditions of the Copay Support Program.

You may be eligible for HEMGENIX if you’re
an adult with hemophilia B and you:

Checkmark icon

Currently use factor IX prophylaxis (prophy) therapy,

Checkmark icon

ORhave current or historical life-threatening bleeding,

Checkmark icon

ORhave repeated, serious spontaneous bleeding episodes.

  • Have poor venous access or require a port
  • Feel limited by or have issues with infusion schedule
  • Feel that current treatment is not meeting goals
  • Have no factor IX inhibitors
  • Are looking for an innovative treatment option
Patient Brochure
Discussion Guide

Get updates and support for HEMGENIX delivered to your inbox

Have questions about HEMGENIX? Join our webinar

Icon of speech bubbles
new

Curious about other patients’ experiences with HEMGENIX?

Connect with them through the HEMGENIX Patient Advocate Program to learn about their treatment journeys, ask questions, and share your own experiences.

Connect with an advocate
Amelia
Virtual Assistant
Hello, I am Amelia. How can I help you today? If this is a medical emergency, please call 911 or report to your local emergency room.
toggle chat overlay toggle chat overlay
Top of Page

IMPORTANT SAFETY INFORMATION

Before you can receive HEMGENIX®, etranacogene dezaparvovec-drlb, your doctor will perform tests to check for Factor IX inhibitors. If you have inhibitors, or have had them in the past, you are not a candidate for HEMGENIX. Your doctor will also check your liver health and screen for hepatitis B and C, as active infection may affect how well the treatment works or increase the risk of side effects.

Infusion-related and allergic reactions (including anaphylaxis) can occur. You will be monitored throughout infusion and for at least 3 hours afterward. If a reaction occurs during infusion, the infusion may be slowed or interrupted as symptoms are addressed, then started at a slower rate once symptoms have resolved.

Liver effects including liver injury can occur. Your doctor will monitor your liver with blood tests every week for 3 months and then monthly up to 1 year after treatment. Increased liver enzymes may require corticosteroid treatment. Because HEMGENIX works in the liver, there is a potential (possible but not proven) risk of liver cancer, and some patients may be monitored for up to 5 years.

After treatment, your body will develop antibodies to HEMGENIX, which may affect how well it works.

Your doctor will monitor Factor IX levels and check for inhibitors. You may still need support to help control bleeding, especially in the initial weeks after treatment.

Most common side effects include increased liver enzymes, headache, increased blood creatine kinase, flu-like symptoms, infusion-related reactions, fatigue, nausea, and feeling unwell. These are not the only side effects possible. Tell your healthcare provider about any side effect you may experience.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.

INDICATION

HEMGENIX is indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:

  • Currently use Factor IX prophylaxis therapy, or
  • Have current or historical life-threatening hemorrhage, or
  • Have repeated, serious spontaneous bleeding episodes.

Please see full prescribing information for HEMGENIX.